PortfoliosLab logo
IDXX vs. ZTS
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between IDXX and ZTS is 0.55, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


-0.50.00.51.0
Correlation: 0.6

Performance

IDXX vs. ZTS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in IDEXX Laboratories, Inc. (IDXX) and Zoetis Inc. (ZTS). The values are adjusted to include any dividend payments, if applicable.

400.00%500.00%600.00%700.00%800.00%900.00%December2025FebruaryMarchAprilMay
898.05%
451.41%
IDXX
ZTS

Key characteristics

Sharpe Ratio

IDXX:

-0.20

ZTS:

-0.06

Sortino Ratio

IDXX:

-0.07

ZTS:

0.09

Omega Ratio

IDXX:

0.99

ZTS:

1.01

Calmar Ratio

IDXX:

-0.14

ZTS:

-0.04

Martin Ratio

IDXX:

-0.38

ZTS:

-0.13

Ulcer Index

IDXX:

17.62%

ZTS:

11.13%

Daily Std Dev

IDXX:

32.93%

ZTS:

24.86%

Max Drawdown

IDXX:

-81.46%

ZTS:

-46.52%

Current Drawdown

IDXX:

-33.21%

ZTS:

-34.90%

Fundamentals

Market Cap

IDXX:

$35.06B

ZTS:

$68.50B

EPS

IDXX:

$10.66

ZTS:

$5.46

PE Ratio

IDXX:

40.59

ZTS:

28.13

PEG Ratio

IDXX:

3.71

ZTS:

2.71

PS Ratio

IDXX:

9.00

ZTS:

7.40

PB Ratio

IDXX:

22.20

ZTS:

14.35

Total Revenue (TTM)

IDXX:

$2.93B

ZTS:

$7.07B

Gross Profit (TTM)

IDXX:

$1.79B

ZTS:

$4.96B

EBITDA (TTM)

IDXX:

$940.32M

ZTS:

$3.00B

Returns By Period

In the year-to-date period, IDXX achieves a 14.01% return, which is significantly higher than ZTS's -3.85% return. Over the past 10 years, IDXX has outperformed ZTS with an annualized return of 21.92%, while ZTS has yielded a comparatively lower 14.00% annualized return.


IDXX

YTD

14.01%

1M

12.62%

6M

15.84%

1Y

0.71%

5Y*

11.77%

10Y*

21.92%

ZTS

YTD

-3.85%

1M

-3.54%

6M

-12.38%

1Y

-0.69%

5Y*

4.93%

10Y*

14.00%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

IDXX vs. ZTS — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

IDXX
The Risk-Adjusted Performance Rank of IDXX is 4040
Overall Rank
The Sharpe Ratio Rank of IDXX is 4141
Sharpe Ratio Rank
The Sortino Ratio Rank of IDXX is 3636
Sortino Ratio Rank
The Omega Ratio Rank of IDXX is 3535
Omega Ratio Rank
The Calmar Ratio Rank of IDXX is 4444
Calmar Ratio Rank
The Martin Ratio Rank of IDXX is 4444
Martin Ratio Rank

ZTS
The Risk-Adjusted Performance Rank of ZTS is 4545
Overall Rank
The Sharpe Ratio Rank of ZTS is 4949
Sharpe Ratio Rank
The Sortino Ratio Rank of ZTS is 4040
Sortino Ratio Rank
The Omega Ratio Rank of ZTS is 3939
Omega Ratio Rank
The Calmar Ratio Rank of ZTS is 5050
Calmar Ratio Rank
The Martin Ratio Rank of ZTS is 4949
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

IDXX vs. ZTS - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for IDEXX Laboratories, Inc. (IDXX) and Zoetis Inc. (ZTS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The chart of Sharpe ratio for IDXX, currently valued at -0.20, compared to the broader market-2.00-1.000.001.002.003.00
IDXX: -0.20
ZTS: -0.06
The chart of Sortino ratio for IDXX, currently valued at -0.07, compared to the broader market-6.00-4.00-2.000.002.004.00
IDXX: -0.07
ZTS: 0.09
The chart of Omega ratio for IDXX, currently valued at 0.99, compared to the broader market0.501.001.502.00
IDXX: 0.99
ZTS: 1.01
The chart of Calmar ratio for IDXX, currently valued at -0.14, compared to the broader market0.001.002.003.004.005.00
IDXX: -0.14
ZTS: -0.04
The chart of Martin ratio for IDXX, currently valued at -0.38, compared to the broader market-10.000.0010.0020.00
IDXX: -0.38
ZTS: -0.13

The current IDXX Sharpe Ratio is -0.20, which is lower than the ZTS Sharpe Ratio of -0.06. The chart below compares the historical Sharpe Ratios of IDXX and ZTS, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.501.00December2025FebruaryMarchAprilMay
-0.20
-0.06
IDXX
ZTS

Dividends

IDXX vs. ZTS - Dividend Comparison

IDXX has not paid dividends to shareholders, while ZTS's dividend yield for the trailing twelve months is around 1.20%.


TTM20242023202220212020201920182017201620152014
IDXX
IDEXX Laboratories, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
ZTS
Zoetis Inc.
1.20%1.06%0.76%0.89%0.41%0.48%0.50%0.59%0.58%0.71%0.69%0.67%

Drawdowns

IDXX vs. ZTS - Drawdown Comparison

The maximum IDXX drawdown since its inception was -81.46%, which is greater than ZTS's maximum drawdown of -46.52%. Use the drawdown chart below to compare losses from any high point for IDXX and ZTS. For additional features, visit the drawdowns tool.


-50.00%-45.00%-40.00%-35.00%-30.00%-25.00%December2025FebruaryMarchAprilMay
-33.21%
-34.90%
IDXX
ZTS

Volatility

IDXX vs. ZTS - Volatility Comparison

IDEXX Laboratories, Inc. (IDXX) has a higher volatility of 17.69% compared to Zoetis Inc. (ZTS) at 11.23%. This indicates that IDXX's price experiences larger fluctuations and is considered to be riskier than ZTS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


5.00%10.00%15.00%December2025FebruaryMarchAprilMay
17.69%
11.23%
IDXX
ZTS

Financials

IDXX vs. ZTS - Financials Comparison

This section allows you to compare key financial metrics between IDEXX Laboratories, Inc. and Zoetis Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


1.00B1.50B2.00BAprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober
954.29M
2.32B
(IDXX) Total Revenue
(ZTS) Total Revenue
Values in USD except per share items

IDXX vs. ZTS - Profitability Comparison

The chart below illustrates the profitability comparison between IDEXX Laboratories, Inc. and Zoetis Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

60.0%65.0%70.0%AprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober
59.8%
69.5%
(IDXX) Gross Margin
(ZTS) Gross Margin
IDXX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, IDEXX Laboratories, Inc. reported a gross profit of 570.66M and revenue of 954.29M. Therefore, the gross margin over that period was 59.8%.
ZTS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Zoetis Inc. reported a gross profit of 1.61B and revenue of 2.32B. Therefore, the gross margin over that period was 69.5%.
IDXX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, IDEXX Laboratories, Inc. reported an operating income of 261.69M and revenue of 954.29M, resulting in an operating margin of 27.4%.
ZTS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Zoetis Inc. reported an operating income of 765.00M and revenue of 2.32B, resulting in an operating margin of 33.0%.
IDXX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, IDEXX Laboratories, Inc. reported a net income of 216.15M and revenue of 954.29M, resulting in a net margin of 22.7%.
ZTS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Zoetis Inc. reported a net income of 581.00M and revenue of 2.32B, resulting in a net margin of 25.1%.